Cabozantinib malate is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It is also effective in managing progressive, metastatic medullary thyroid cancer (MTC). In addition, it is approved for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. The drug works by inhibiting multiple tyrosine kinases, including MET, VEGFR2, and RET, which are involved in tumor growth, angiogenesis, and metastasis. This makes it a valuable option for patients who have not responded well to other therapies. Cabozantinib malate is a specialty chemical used as an active pharmaceutical ingredient (API) in oncology research and drug development.